Search results for "Respimat"

showing 10 items of 25 documents

Once-daily tiotropium Respimat® 5 μg is an efficacious 24-h bronchodilator in adults with symptomatic asthma

2015

SummaryIntroductionOnce-daily tiotropium Respimat® 5 μg is an efficacious add-on therapy to inhaled corticosteroids (ICS) with or without long-acting β2-agonists in patients with symptomatic asthma. The objective of this study was to investigate whether the dosing regimen of tiotropium (once- versus twice-daily), delivered via the Respimat® SoftMist™ inhaler, affected 24-h bronchodilator efficacy and safety versus placebo Respimat® in patients with asthma who were symptomatic despite medium-dose ICS therapy.MethodsA randomised, double-blind, placebo-controlled, crossover study with 4-week treatment periods of tiotropium 5 μg (once-daily, evening) and 2.5 μg (twice-daily, morning and evening…

AdultEstoniaMalePulmonary and Respiratory MedicineVital capacityRespimatEveningAdolescentmedicine.drug_classPlaceboDouble-Blind MethodRisk FactorsAnticholinergic drugForced Expiratory VolumeGermanyBronchodilatorAdministration InhalationmedicineHumansDosingDosing regimenTiotropium BromideAgedCzech RepublicAsthmaLong-acting bronchodilatorCross-Over StudiesDose-Response Relationship Drugbusiness.industryTiotropiumInhalerMiddle Agedmedicine.diseaseLatviaAsthmaBronchodilator Agentsrespiratory tract diseasesTreatment OutcomeBronchodilator efficacyAustriaAnesthesiaFemalebusinessRespiratory Medicine
researchProduct

Tiotropium Respimat® in asthma: a double-blind, randomised, dose-ranging study in adult patients with moderate asthma

2013

Tiotropium, a once-daily long-acting anticholinergic bronchodilator, when administered via Respimat® SoftMist™ inhaler (tiotropium Respimat®) significantly reduces the risk of severe exacerbations and improves lung function in patients with severe persistent asthma that is not fully controlled despite using inhaled corticosteroids (ICS) and long-acting β2-agonists. To further explore the dose–response curve in asthma, we investigated the efficacy and safety of three different doses of tiotropium Respimat® as add-on to ICS in symptomatic patients with moderate persistent asthma. In this randomised, double-blind, placebo-controlled, four-way crossover study, patients were randomised to tiotro…

AdultMalePulmonary and Respiratory MedicineRespimatmedicine.drug_classScopolamine DerivativesPlaceboFEV1/FVC ratioDouble-Blind MethodCholinergic antagonistsBronchodilatorAdministration InhalationmedicineHumansTiotropium BromideAsthmaCross-Over StudiesDose-Response Relationship Drugbusiness.industryResearchTiotropiumTiotropium bromideMiddle AgedBronchodilator agentsmedicine.diseaseDose-ranging studyCrossover studyAsthmaRespimatrespiratory tract diseasesClinical trialAnesthesiaFemalebusinessmedicine.drugFollow-Up StudiesRespiratory Research
researchProduct

24-h efficacy and pharmacokinetics of tiotropium Respimat® 5 μg in patients with asthma

2015

Background: Once-daily tiotropium Respimat® (tioR) add-on therapy has demonstrated efficacy in patients with moderate symptomatic asthma. Aim and Objectives: To investigate whether dosing regimen (QD vs BID) affected 24-h bronchodilator efficacy and exposure of tioR. Methods: 2 randomised, double-blind, crossover trials (trial 1, NCT01152450 [placebo-controlled]; trial 2, NCT01696071); 4-week treatments of tioR 5 µg QD, 2.5 µg BID and placebo Respimat® (pboR) added to medium-dose ICS (400-800 µg budesonide or equivalent). Primary end point (Week 4): area under the curve response for FEV1 (FEV1 AUC(0-24h)) (trial 1, tioR vs pboR; trial 2, QD vs BID). Pharmacokinetic end points (steady state)…

Budesonidemedicine.medical_specialtyRespimatmedicine.drug_classbusiness.industryArea under the curvePlaceboGastroenterologyPharmacokineticsInternal medicineBronchodilatormedicineClinical endpointDosingbusinessmedicine.drug5.3 Allergy and Immunology
researchProduct

In vitro dose comparison of Respimat<sup>®</sup> inhaler with dry powder inhalers for COPD maintenance therapy

2017

Background Combining in vitro mouth-throat deposition measurements, cascade impactor data and computational fluid dynamics (CFD) simulations, four different inhalers were compared which are indicated for chronic obstructive pulmonary disease (COPD) treatment. Methods The Respimat inhaler, the Breezhaler, the Genuair, and the Ellipta were coupled to the idealized Alberta throat model. The modeled dose to the lung (mDTL) was collected downstream of the Alberta throat model using either a filter or a next generation impactor (NGI). Idealized breathing patterns from COPD patient groups - moderate and very severe COPD - were applied. Theoretical lung deposition patterns were assessed by an indiv…

COPDRespimatInhalationbusiness.industryInhalerGeneral MedicineTiotropium bromidemedicine.disease03 medical and health scienceschemistry.chemical_compound0302 clinical medicinemedicine.anatomical_structure030228 respiratory systemchemistryAnesthesiaThroatmedicine030212 general & internal medicineVilanterolbusinessFluticasonemedicine.drugInternational Journal of Chronic Obstructive Pulmonary Disease
researchProduct

Efficacy of tiotropium and olodaterol fixed-dose combination in patients with COPD on β-blockers

2015

Introduction: The efficacy and safety of a new once-daily (QD) fixed-dose combination (FDC) with tiotropium (T), a long-acting muscarinic antagonist, and olodaterol (O), a long-acting β 2 -agonist, was established for the treatment of COPD in the TONADO studies (NCT01431274; NCT01431287). This analysis evaluates the efficacy of the FDC in a subpopulation of patients receiving β-blockers (BBs) in these studies. Methods: Two replicate, randomised, double-blind, parallel-group, 52-week, Phase III trials assessed the efficacy and safety of T+O FDC (2.5/5 μg; 5/5 μg; Respimat ® inhaler) QD compared to the monocomponents. Key primary end point data for the combined analysis of the replicate trial…

COPDmedicine.medical_specialtyRespimatbusiness.industryInhalerOlodaterolFixed-dose combinationMuscarinic antagonistmedicine.diseasechemistry.chemical_compoundchemistryInternal medicinemedicinePhysical therapyClinical endpointIn patientbusinessmedicine.drug5.1 Airway Pharmacology and Treatment
researchProduct

Inhalation therapy devices for the treatment of obstructive lung diseases: the history of inhalers towards the ideal inhaler.

2020

Inhalation therapy allows conveying drugs directly into the airways. The devices used to administer inhaled drugs play a crucial role in the management of obstructive lung diseases such as asthma and chronic obstructive pulmonary disease (COPD). To ensure high bronchial deposition of the drug, a device should deliver a high proportion of fine particles, be easy to use, and provide constant and accurate doses of the active substance. Nowadays, four different types of inhalers are widely used: nebulizers, dry powder inhalers (DPIs), pressurized metered-dose inhalers (pMDIs), and soft mist inhalers (SMIs). Nebulizers can be used by patients unable to use other inhalers. However, they require l…

Drugmedicine.medical_specialtyRespiratory TherapyRespimatmedia_common.quotation_subjectSettore MED/10 - Malattie Dell'Apparato Respiratorio030204 cardiovascular system & hematologyMDI03 medical and health sciencesRoute of administrationPulmonary Disease Chronic Obstructive0302 clinical medicineAsthma COPD DPI MDI Nebulizer RespimatAdministration InhalationInternal MedicinemedicineCOPDHumans030212 general & internal medicineMetered Dose InhalersIntensive care medicineAsthmamedia_commonCOPDInhalationbusiness.industryInhalerNebulizers and VaporizersNebulizerEquipment Designmedicine.diseaseAsthma; COPD; DPI; MDI; Nebulizer; RespimatAsthmaRespimatDPINebulizerbusinessEuropean journal of internal medicine
researchProduct

P294 Benefits of tiotropium/olodaterol over tiotropium at delaying clinically significant events in patients with copd classified as gold B

2016

Rationale The once-daily combination of tiotropium (T), a long-acting muscarinic antagonist, and olodaterol (O), a long-acting β 2 -agonist, has demonstrated efficacy and safety in COPD. Two large clinical studies (TONADO ® 1 + 2) have also demonstrated the benefits of T/O compared to the monocomponents in patients with moderate to very severe COPD. This post hoc analysis investigated whether T/O is more effective than T at delaying clinically significant events in patients with GOLD stage B COPD. Methods A total of 5162 patients were randomised to O 5 µg, T 2.5 µg, T 5 µg, T/O 2.5/5 µg or T/O 5/5 µg (delivered via Respimat ® inhaler) in two 52-week, parallel-group, double-blind studies (NC…

Pulmonary and Respiratory Medicine030213 general clinical medicineCOPDmedicine.medical_specialtyRespimatExacerbationbusiness.industryInhalerOlodaterolmedicine.diseaseGastroenterology03 medical and health scienceschemistry.chemical_compound0302 clinical medicinechemistry030220 oncology & carcinogenesisInternal medicinePost-hoc analysismedicineIn patientRespiratory systembusinessThorax
researchProduct

Efficacy of once-daily tiotropium Respimat in adults with asthma at GINA Steps 2-5.

2020

Tiotropium Respimat is an efficacious add-on to maintenance treatment in patients with symptomatic asthma. Currently, the Global Initiative for Asthma (GINA) strategy recommends tiotropium for patients at Steps 4–5. To assess the clinical benefits of tiotropium Respimat across asthma severities, GINA Steps 2–5, a post hoc analysis of five double-blind trials (12–48-weeks; patients aged 18–75 years) investigated the effect of tiotropium Respimat, 5 μg or 2.5 μg, versus placebo, on peak forced expiratory volume in 1 s (FEV1) within 3 h post-dose (FEV1(0–3h)) response, and Asthma Control Questionnaire-7 (ACQ-7) responder rate. GINA step grouping was based on patients’ background treatment regi…

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyRespimatAdolescentINHALED CORTICOSTEROIDSPlaceboSALMETEROLDouble-Blind MethodADD-ONStatistical significanceInternal medicineAsthma controlPost-hoc analysisAdministration InhalationmedicineHumansPharmacology (medical)Tiotropium BromideCOMBINATIONDisease severityLungAsthmaAgedbusiness.industryTiotropiumBiochemistry (medical)IMPROVES LUNG-FUNCTIONOdds ratioMiddle Agedmedicine.diseaseGINAConfidence intervalLung functionAsthmarespiratory tract diseasesBronchodilator AgentsTreatment OutcomeSAFETYFemaleSalmeterolbusinessmedicine.drugSYMPTOMATIC ASTHMAPulmonary pharmacologytherapeutics
researchProduct

P149 Once-daily tiotropium Respimat® add-on to at least ICS in adult patients with symptomatic asthma: pooled safety analysis: Abstract P149 Table 1

2015

Background A high proportion of patients with asthma are symptomatic despite at least ICS maintenance therapy. Five trials aimed to evaluate the safety of tiotropium Respimat® compared with placebo Respimat®, each as add-on to at least ICS in adult patients with symptomatic asthma. Methods Five Phase III and one Phase II randomised, double-blind, placebo-controlled, parallel-group trials. PrimoTinA-asthma® (48 weeks): tiotropium Respimat® 5 µg add-on to ICS + LABA (≥800 µg budesonide or equivalent); MezzoTinA-asthma® (24 weeks): tiotropium Respimat® 5 µg or 2.5 µg add-on to ICS (400–800 µg budesonide or equivalent); GraziaTinA-asthma® (12 weeks): tiotropium Respimat® 5 µg or 2.5 µg add-on t…

Pulmonary and Respiratory MedicineBudesonideRespimatAdult patientsbusiness.industrymedicine.diseasePlacebohumanitiesrespiratory tract diseasesSafety profileMaintenance therapyAnesthesiamedicineOnce dailybusinesshuman activitiesmedicine.drugAsthmaThorax
researchProduct

P260 Tiotropium Respimat(R) Add-on To Inhaled Corticosteroids Improves Lung Function In Patients With Symptomatic Mild Asthma: Results From A Phase I…

2014

Background Despite currently available therapies and detailed guidelines, many people with mild asthma remain symptomatic; it is important to establish the efficacy and safety of new treatments in this group. Methods A Phase III, randomised, double-blind, parallel-group trial (GraziaTinA-asthma ® ; NCT01316380) evaluated the efficacy and safety of once-daily tiotropium 5 µg or 2.5 µg versus placebo (all delivered via the Respimat ® SoftMist™ inhaler) for 12 weeks in patients with symptomatic asthma on low-dose inhaled corticosteroids (200–400 µg budesonide or equivalent). The primary end point was peak forced expiratory volume in 1 second (FEV 1 ) within 3 h of dosing (0–3h) response (chang…

Pulmonary and Respiratory MedicineBudesonideRespimatbusiness.industryInhalerArea under the curvePlacebomedicine.diseaserespiratory tract diseasesAnesthesiamedicineDosingAdverse effectbusinessmedicine.drugAsthmaThorax
researchProduct